医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KCR Opens New Branch in Sydney, Australia

2021年03月03日 PM10:00
このエントリーをはてなブックマークに追加


 

BOSTON, Mass.

KCR, the international clinical development solutions provider, today announced the establishment of a new branch in Sydney, Australia. The new location will enhance KCR’s regional coverage and maximize clinical capabilities for clients across the globe.

President & CEO, Mike Jagielski commented, “We are very pleased with the move. We’ve observed steady interest in expanding to this region from our primary biotechnology clients in Boston, and Sydney has a reputation for its strong clinical development potential. We are excited that despite recent challenging circumstances, we are able to realize this important element of our organic growth strategy.”

Australia boasts high quality scientific and medical research sites as well as a highly trained clinical workforce that will allow US-based clients to broaden the scope of clinical trials while maintaining their standards for quality and scientific excellence. The opening reinforces KCR’s commitment to supporting clients with international trial execution expertise.

The Sydney location will be the company’s first office outside of its European and American hubs. KCR has further plans to open an Asian hub in South Korea once pandemic travel restrictions are lifted.

If you are interested in cooperating with KCR Australia or would like to learn more about our organization, please contact us at pr@kcrcro.com.

About KCR:

KCR is a clinical development solutions provider for the biotechnology and pharmaceutical industries. We support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates now across five main regions: North America, Western Europe, Central Europe, Eastern Europe and Australia, with a main operational hub located in Boston, MA. Our strategic hub locations, technical capabilities and solution offerings allow for the optimized delivery of trial execution strategies to develop life-changing therapies. KCR offers access to an estimated population of 1.1 Billion people. For more information visit www.kcrcro.com.

We see the human behind every number.

###

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005086/en/

CONTACT

Molly Garrity

KCR, PR & Marketing

E-mail: molly.garrity@kcrcro.com

Mobile: +1 857 753 7853

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates